Haptoglobin (Hp) is a plasma glycoprotein synthesized by hepatocytes and secreted in response to inflammation and infection. 1 The main role of Hp is to bind free haemoglobin (Hb) released during the intravascular destruction of erythrocytes, 2, 3 forming the Hp-Hb complex, and by doing so, to prevent oxidative stress on the vasculature. There are two common alleles of Hp gene: Hp1 and Hp2 -with homozygous (1-1 or 2-2) and heterozygous (2-1) genotypes. 4, 5 Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in patients with diabetes. Multiple clinical studies suggested that Hp polymorphism is a risk factor for the development of CVD and an independent predictor of cardiovascular outcomes in these patients. [6] [7] [8] [9] Furthermore, the evidence suggests that Hp2-2 genotype is associated with an increased risk of CVD in patients with both type 1 and type 2 diabetes. In the Strong Heart Study, patients with diabetes and Hp2-2 genotype had five times greater risk of being diagnosed with CVD in comparison with Hp1-1 genotype. 6 Meta-analysis also confirmed that Hp2-2 genotype is associated with a high risk of cardiovascular events in patients with diabetes. 10 Potential mechanism by which Hp2-2 genotype may cause increased risk of vascular complications is via elevated oxidative stress and/or inflammation. Therefore, decreasing oxidative stress in patients with diabetes using antioxidant supplements may help reduce the risk of cardiovascular events. Furthermore, there are supporting data suggesting that Hp genotype could help identify the patients who might benefit from antioxidant therapy.
This potentially important clinical topic was thoroughly explored in a review by Dalan and Liuh Ling, 11 published in the European Journal of Preventive Cardiology. They analysed data on different aspects of Hp and Hp-genotypes in molecular, translational and clinical studies. After providing details on the Hp gene, its polymorphisms and antioxidant role, they address inconsistent data on the association of specific Hp genotypes and diabetes, atherosclerosis, endothelial function and arterial stiffness. In addition, clinical studies on the associations of Hp genotypes and vascular complications in patients with type 1 and type 2 diabetes were explored. The authors summarize the results from three studies in patients with type 1 diabetes, hypothesizing that the Hp2-2 genotypes confer a higher risk of cardiovascular complications. The same was true for patients with type 2 diabetes, in whom there was a more consistent association of Hp genotypes with cardiovascular complications. Namely, Hp2-1 individuals had higher risk of hypertension and dyslipidaemia, while Hp2-2 genotype has been associated with subclinical atherosclerosis, 12 CVD and CVD mortality. 6 No associations of Hp genotype and microvascular complications were observed. 13 The authors also provided a critical overview on the effect of vitamin E treatment in reducing the risk of diabetes complications, raising several important issues. The most relevant may be the lack of evidence suggesting clinical efficacy of vitamin E treatment, as well as a yet unidentified subgroup of patients who may benefit from such treatment.
A comprehensive meta-analysis of 24 observational studies found that circulating levels of total tocopherols (compounds of vitamin E), but not a-tocopherol (the most biologically active form of vitamin E), were significantly lower in patients with coronary artery disease than in controls.
14 Vitamin E has been shown to have the ability to scavenge lipid radicals and terminate oxidative chain reactions, and by doing so, acts as an antioxidant. 15, 16 In preclinical models, it has been shown that vitamin E has favourable cardiovascular effects, by inhibiting L oxidation of low-density lipoprotein cholesterol in plasma. 17 In addition, promising results of observational studies have provided rationale for conducting randomized clinical trials investigating the protective role of vitamin E in CVD.
One of the first studies that investigated the role of vitamin E in primary prevention of CVD included 27,271 patients (male, smokers, 50-69 years old, without a history of myocardial infarction (MI)) randomized to vitamin E (50 mg/day), beta-carotene (20 mg/ day), both, or placebo for a median of 6.1 years. Although the incidence of MI was 4% lower in patients randomized to vitamin E, the difference among groups was not statistically significant. 18 Similar results were found in the Collaborative Group of the Primary Prevention Project, 19 which randomized 4495 patients with one or more cardiovascular risk factor to aspirin (100 mg/day) or vitamin E (300 mg/day). The study was terminated prematurely when beneficial effects of aspirin in primary prevention were revealed (in the other study), but no favourable data of vitamin E treatment was observed. In addition, among a subgroup of patients with diabetes, there was no benefit of vitamin E treatment. 20 The Women's Health Study randomly assigned 39,876 women (more than 45 years old) to vitamin E (600 IU), aspirin, or placebo, which were followed for an average of 10.1 years. 21 Treatment with vitamin E decreased cardiovascular death by 24% (relative risk (RR), 0.76; 95% confidence interval (CI), 0.59-0.98; p ¼ 0.03), but not the number of major cardiovascular events and total mortality. In the Physicians Health Study, 14,641 males (older than 50 years, 94.9% free from cardiovascular disease) were randomized to vitamin E (400 IU every other day) or vitamin C (500 mg/day) but neither had an effect on cardiovascular outcomes. However, vitamin E was associated with an increased risk of haemorrhagic stroke (hazard ratio, 1.74; 95% CI, 1.04-2.91; p ¼ 0.036). 22 Trials investigating the effect of vitamin E in the secondary prevention of CVD also had controversial results. The Cambridge Heart Antioxidant Study 23 investigated the effects of vitamin E (400 IU/day or 800 IU/day) on the risk of cardiovascular death and non-fatal MI in about 2000 patients with overt atherosclerosis. The risk of cardiovascular death and nonfatal MI was significantly reduced (RR 0.53, p ¼ 0.005), with MI being the contributing factor. The Heart and Outcomes Prevention Evaluation (HOPE) study randomly assigned 9541 patients at high risk for cardiovascular events to vitamin E (400 IU/day) or placebo, and either an angiotensin-converting enzyme inhibitor (ramipril) or placebo, for a mean of 4.5 years. 24 There were no differences between the randomized groups in the combined outcome of cardiovascular death, non-fatal MI and stroke, as well as the components, suggesting that vitamin E had no effect on cardiovascular outcomes in this high-risk population. Results were similar in subgroups of patients with diabetes 25 and chronic kidney injury. 26 Furthermore, in the HOPE-The Ongoing Outcomes study 27 patients receiving vitamin E had a higher risk of heart failure (RR, 1.13; 95% CI, 1.01-1.26; p ¼ 0.03) and hospitalization for heart failure (RR, 1.21; 95% CI, 1.00-1.47; p ¼ 0.045). In the Heart Protection Study, among 20,536 high-risk adults, antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) did not have any effect on major outcomes. 28 However, among patients on haemodialysis with CVD enrolled in the Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease trial 29 beneficial effect of vitamin E supplementation was observed on the composite outcome (MI, ischaemic stroke, peripheral vascular disease and unstable angina). Data on the protective role of vitamin E in prevention of cardiovascular events is inconsistent, and therefore use of these agents in patients with diabetes currently cannot be recommended.
Although both HOPE and the Women's Health Study showed no benefit with vitamin E treatment in the prevention of CVD in entire cohorts of patients with diabetes, the results were different for a subgroup of individuals with diabetes mellitus and Hp2-2 genotype. In HOPE, among this subgroup of patients, vitamin E significantly reduced the risk of MI and cardiovascular death, but not stroke, compared with placebo. 24 Similarly, in the Women's Health Study vitamin E use was associated with a non-significant 15% reduction of cardiovascular events compared with a 20-25% increase in non-Hp2-2 individuals with diabetes. 21 Finally, the Israel Cardiovascular Vitamin E study was the first prospective clinical trial evaluating the effect of vitamin E therapy in 1434 patients with diabetes and Hp2-2 genotype. After 18 months, the rate of primary outcomes (stroke, MI and cardiovascular death) was significantly lower in those treated with vitamin E (2.2%) compared with placebo (4.7%), 30 indicating that vitamin E may significantly reduce the risk of CVD. This was also confirmed in the meta-analysis, where vitamin E had favourable effects on cardiovascular endpoint in patients with diabetes and Hp2-2 genotype. 10 Therefore, the cardioprotectivity of vitamin E may be effective in more severe patients group, who have high levels of oxidative stress, such as those on haemodialysis.
All of the abovementioned studies provide evidence that among patients with diabetes, Hp2-2 genotype may be associated with a higher risk for CVD. In addition, intervention with vitamin E significantly decreased this risk, and suggests that this genotype may serve as a predictive biomarker for the benefit in vitamin E therapy. Taking into account that the frequencies of the Hp genotypes in the Western world are approximately 16% (Hp1-1), 48% (Hp2-1) and 36% (Hp2-2), 4, 5 identifying those at high risk would be very useful. Larger controlled clinical trials are needed to investigate whether novel pharmacogenomic approaches, such as Hp genotyping, may help in targeting the antioxidant treatment towards patients with diabetes, who might gain most benefit, and further lead to reduction of cardiovascular complications.
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